Alzheimer's Disease CSF Biomarkers As Possible Indicators of Tap-Test Response in Idiopathic Normal Pressure Hydrocephalus

Overview

Journal Brain Sci

Publisher MDPI

Date 2023 Nov 25

PMID 38002553

Authors

Efstratios-Stylianos Pyrgelis

George P Paraskevas

Vasilios C Constantinides

Fotini Boufidou

Myrto Papaioannou

Leonidas Stefanis

Elisabeth Kapaki

Affiliations

Soon will be listed here.

Abstract

The aim of the present study is the evaluation of established Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers in patients with idiopathic normal-pressure hydrocephalus (iNPH), both individually and as a total profile, and the investigation of their use as potential predictors of Tap-test responsiveness. Fifty-three patients with iNPH participated in the study. Aβ42, Aβ40, total Tau and phospho-Tau proteins were measured in duplicate with double-sandwich ELISA assays. Clinical evaluation involved a 10 m timed walk test before an evacuative lumbar puncture (LP) and every 24 h for three consecutive days afterwards. Neuropsychological assessment involved a mini-mental state examination, frontal assessment battery, 5-word test and CLOX drawing test 1 and 2, which were also performed before and 48 h after LP. Response in the Tap-test was defined as a 20% improvement in gait and/or a 10% improvement in neuropsychological tests. The Aβ42/Aβ40 ratio was found to be significantly higher in Tap-test responders than non-responders. Total Tau and phospho-Tau CSF levels also differed significantly between these two groups, with Tap-test responders presenting with lower levels compared to non-responders. Regarding the AD CSF biomarker profile (decreased amyloid and increased Tau proteins levels), patients with a non-AD profile were more likely to have a positive response in the Tap-test than patients with an AD profile.

Citing Articles

Cerebrospinal Fluid Classical Biomarker Levels in Mixed vs. Pure AT (AT) Alzheimer's Disease.

Tsantzali I, Athanasaki A, Boufidou F, Constantinides V, Stefanou M, Moschovos C Biomedicines. 2025; 12(12.

PMID: 39767810 PMC: 11672946. DOI: 10.3390/biomedicines12122904.

In Vivo Prevalence of Beta-Amyloid Pathology and Alzheimer's Disease Co-Pathology in Idiopathic Normal-Pressure Hydrocephalus-Association with Neuropsychological Features.

Pyrgelis E, Paraskevas G, Constantinides V, Boufidou F, Stefanis L, Kapaki E Biomedicines. 2024; 12(8).

PMID: 39200362 PMC: 11351685. DOI: 10.3390/biomedicines12081898.

References

Constantinides V, Paraskevas G, Boufidou F, Bourbouli M, Pyrgelis E, Stefanis L . CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer's Disease and Frontotemporal Dementias. Diagnostics (Basel). 2023; 13(4). PMC: 9955886. DOI: 10.3390/diagnostics13040783. View

Simonsen A, Herukka S, Andreasen N, Baldeiras I, Bjerke M, Blennow K . Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimers Dement. 2017; 13(3):274-284. DOI: 10.1016/j.jalz.2016.09.008. View

Kapaki E, Paraskevas G, Papageorgiou S, Bonakis A, Kalfakis N, Zalonis I . Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2008; 22(1):47-53. DOI: 10.1097/WAD.0b013e3181610fea. View

Akiba C, Nakajima M, Miyajima M, Ogino I, Motoi Y, Kawamura K . Change of Amyloid-β 1-42 Toxic Conformer Ratio After Cerebrospinal Fluid Diversion Predicts Long-Term Cognitive Outcome in Patients with Idiopathic Normal Pressure Hydrocephalus. J Alzheimers Dis. 2018; 63(3):989-1002. PMC: 6004932. DOI: 10.3233/JAD-180059. View

Williams M, Relkin N . Diagnosis and management of idiopathic normal-pressure hydrocephalus. Neurol Clin Pract. 2013; 3(5):375-385. PMC: 3806933. DOI: 10.1212/CPJ.0b013e3182a78f6b. View

Paraskevas G, Kasselimis D, Kourtidou E, Constantinides V, Bougea A, Potagas C . Cerebrospinal Fluid Biomarkers as a Diagnostic Tool of the Underlying Pathology of Primary Progressive Aphasia. J Alzheimers Dis. 2016; 55(4):1453-1461. DOI: 10.3233/JAD-160494. View

Muller-Schmitz K, Krasavina-Loka N, Yardimci T, Lipka T, Kolman A, Robbers S . Normal Pressure Hydrocephalus Associated with Alzheimer's Disease. Ann Neurol. 2020; 88(4):703-711. DOI: 10.1002/ana.25847. View

Nakajima M, Yamada S, Miyajima M, Ishii K, Kuriyama N, Kazui H . Guidelines for Management of Idiopathic Normal Pressure Hydrocephalus (Third Edition): Endorsed by the Japanese Society of Normal Pressure Hydrocephalus. Neurol Med Chir (Tokyo). 2021; 61(2):63-97. PMC: 7905302. DOI: 10.2176/nmc.st.2020-0292. View

Siraj S . An overview of normal pressure hydrocephalus and its importance: how much do we really know?. J Am Med Dir Assoc. 2011; 12(1):19-21. DOI: 10.1016/j.jamda.2010.05.005. View

10.

Kubo Y, Kazui H, Yoshida T, Kito Y, Kimura N, Tokunaga H . Validation of grading scale for evaluating symptoms of idiopathic normal-pressure hydrocephalus. Dement Geriatr Cogn Disord. 2007; 25(1):37-45. DOI: 10.1159/000111149. View

11.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

12.

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

13.

Agren-Wilsson A, Lekman A, Sjoberg W, Rosengren L, Blennow K, Bergenheim A . CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus. Acta Neurol Scand. 2007; 116(5):333-9. DOI: 10.1111/j.1600-0404.2007.00890.x. View

14.

Adams R, Fisher C, Hakim S, Ojemann R, SWEET W . SYMPTOMATIC OCCULT HYDROCEPHALUS WITH "NORMAL" CEREBROSPINAL-FLUID PRESSURE. A TREATABLE SYNDROME. N Engl J Med. 1965; 273:117-26. DOI: 10.1056/NEJM196507152730301. View

15.

Kang K, Ko P, Jin M, Suk K, Lee H . Idiopathic normal-pressure hydrocephalus, cerebrospinal fluid biomarkers, and the cerebrospinal fluid tap test. J Clin Neurosci. 2014; 21(8):1398-403. DOI: 10.1016/j.jocn.2013.11.039. View

16.

Ransohoff J, Shulman K, Fishman R . Hydrocephalus: a review of etiology and treatment. J Pediatr. 1960; 56:399-411. DOI: 10.1016/s0022-3476(60)80193-x. View

17.

Santangelo R, Cecchetti G, Bernasconi M, Cardamone R, Barbieri A, Pinto P . Cerebrospinal Fluid Amyloid-β 42, Total Tau and Phosphorylated Tau are Low in Patients with Normal Pressure Hydrocephalus: Analogies and Differences with Alzheimer's Disease. J Alzheimers Dis. 2017; 60(1):183-200. DOI: 10.3233/JAD-170186. View

18.

Golomb J, Wisoff J, Miller D, Boksay I, Kluger A, Weiner H . Alzheimer's disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response. J Neurol Neurosurg Psychiatry. 2000; 68(6):778-81. PMC: 1736969. DOI: 10.1136/jnnp.68.6.778. View

19.

Dubois B, Touchon J, Portet F, Ousset P, Vellas B, Michel B . ["The 5 words": a simple and sensitive test for the diagnosis of Alzheimer's disease]. Presse Med. 2002; 31(36):1696-9. View

20.

Molinuevo J, Blennow K, Dubois B, Engelborghs S, Lewczuk P, Perret-Liaudet A . The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement. 2014; 10(6):808-17. DOI: 10.1016/j.jalz.2014.03.003. View